Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 109

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma

Simon, Elana P., Freije, Catherine A., Farber, Benjamin A., Lalazar, Gadi, Darcy, David G., Honeyman, Joshua N., Chiaroni-Clarke, Rachel, Dill, Brian D., Molina, Henrik, Bhanot, Umesh K., La Quaglia, Michael P., Rosenberg, Brad R., Simon, Sanford M. · 2015 · Proceedings of the National Academy of Sciences

Abstract

Significance: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare pediatric liver cancer. A deletion of ∼400 kb in one copy of chromosome 19 results in a chimeric protein, an activated protein kinase A. No other deletions, amplifications, mutations, or structural variants were found. This strongly implicates the chimera as the driving mutation. This paper examines gene expression in FLHCC. The results establish FLHCC as a single disease distinct from other cancers, including hepatocellular carcinoma. The results help explain some of the known pathophysiology: the collagen fibers that give fibrolamellar its name and the gynecomastia reported in young male patients. Finally, this work identifies oncogenes whose expression is increased and that may serve as targets for therapeutic intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1424894112

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 94

  1. HA Edmondson, Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 91, 168–186 (1956).
  2. JR Craig, RL Peters, HA Edmondson, M Omata, Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46, 372–379 (1980). · doi:10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s
  3. M Torbenson, Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo) 2012, 743790 (2012).
  4. HM Katzenstein, , Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 97, 2006–2012 (2003). · DOI
  5. VB Weeda, , Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer 49, 2698–2704 (2013). · DOI
  6. AO Kaseb, , Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 85, 197–203 (2013). · doi:10.1159/000354698
  7. HB El-Serag, JA Davila, Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 39, 798–803 (2004). · DOI
  8. AD Pinna, , Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 26, 877–883 (1997). · doi:10.1002/hep.510260412
  9. MN Mavros, SC Mayo, O Hyder, TM Pawlik, A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 215, 820–830 (2012). · DOI
  10. G Malouf, , Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol 62, 519–524 (2009). · DOI
  11. AG Nerlich, , Excessive collagen formation in fibrolamellar carcinoma of the liver: A morphological and biochemical study. Mod Pathol 5, 580–585 (1992).
  12. MA Berman, JA Burnham, DG Sheahan, Fibrolamellar carcinoma of the liver: An immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 19, 784–794 (1988). · doi:10.1016/s0046-8177(88)80261-2
  13. CS Ang, , Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: Data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 6, 3–9 (2013).
  14. SC Ward, , Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 23, 1180–1190 (2010). · doi:10.1038/modpathol.2010.105
  15. GG Malouf, , Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology 59, 2228–2237 (2014). · DOI
  16. L Xu, , Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet 24, 50–63 (2015). · DOI · Paper page
  17. VR Agarwal, , Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab 83, 1797–1800 (1998).
  18. MA Hany, , A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol 28, 136–138 (1997). · doi:10.1002/(sici)1096-911x(199702)28:2<136::aid-mpo8>3.0.co;2-l
  19. R Kannangai, P Vivekanandan, F Martinez-Murillo, M Choti, M Torbenson, Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 38, 639–644 (2007). · doi:10.1016/j.humpath.2006.07.019
  20. JN Honeyman, , Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010–1014 (2014). · DOI · Paper page
  21. DG Darcy, , The genomic landscape of fibrolamellar hepatocellular carcinoma: Whole genome sequencing of ten patients. Oncotarget 6, 755–770 (2015). · DOI
  22. SS Taylor, R Ilouz, P Zhang, AP Kornev, Assembly of allosteric macromolecular switches: Lessons from PKA. Nat Rev Mol Cell Biol 13, 646–658 (2012). · DOI · Paper page
  23. AJ Shaywitz, ME Greenberg, CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68, 821–861 (1999). · DOI · Paper page
  24. JJ Tremblay, F Hamel, RS Viger, Protein kinase A-dependent cooperation between GATA and CCAAT/enhancer-binding protein transcription factors regulates steroidogenic acute regulatory protein promoter activity. Endocrinology 143, 3935–3945 (2002). · DOI
  25. M Naumann, C Scheidereit, Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J 13, 4597–4607 (1994). · DOI · Paper page
  26. M Zhang, , Protein kinase A activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies. PLoS One 9, e109523 (2014). · DOI
  27. F-X Yu, , Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Development 27, 1223–1232 (2013). · DOI · Paper page
  28. JL Baert, C Beaudoin, L Coutte, Y de Launoit, ERM transactivation is up-regulated by the repression of DNA binding after the PKA phosphorylation of a consensus site at the edge of the ETS domain. J Biol Chem 277, 1002–1012 (2002). · DOI
  29. T Mao, , PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism. Proc Natl Acad Sci USA 108, 15852–15857 (2011). · DOI
  30. AM Lerario, A Moraitis, GD Hammer, Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 386, 67–84 (2014). · DOI
  31. J Baselga, SM Swain, Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9, 463–475 (2009). · DOI · Paper page
  32. S Anders, W Huber, Differential expression analysis for sequence count data. Genome Biol 11, R106 (2010). · DOI · Paper page
  33. Y-H Wu, T-H Chang, Y-F Huang, H-D Huang, C-Y Chou, COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene 33, 3432–3440 (2013). · DOI · Paper page
  34. J Jagirdar, KG Ishak, M Colombo, C Brambilla, F Paronetto, Fibronectin patterns in hepatocellular carcinoma and its clinical significance. Cancer 56, 1643–1648 (1985). · doi:10.1002/1097-0142(19851001)56:7<1643::aid-cncr2820560730>3.0.co;2-o
  35. M Torbenson, , Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 15, 826–830 (2002). · doi:10.1097/01.mp.0000024257.83046.7c
  36. P Van Eyken, , Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 17, 101–107 (1990). · doi:10.1111/j.1365-2559.1990.tb00679.x
  37. MW Pickup, JK Mouw, VM Weaver, The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15, 1243–1253 (2014). · DOI · Paper page
  38. Y Hoshida, , Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359, 1995–2004 (2008). · DOI · Paper page
  39. CHC Sukowati, , The expression of CD90/Thy-1 in hepatocellular carcinoma: An in vivo and in vitro study. PLoS One 8, e76830 (2013). · DOI
  40. M Reedijk, , High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65, 8530–8537 (2005). · DOI · Paper page
  41. DW Kufe, Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 9, 874–885 (2009). · DOI · Paper page
  42. BM Ku, , CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 128, 1316–1326 (2011). · DOI
  43. M Kawada, , Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31, 3111–3123 (2012). · DOI · Paper page
  44. PL Mellon, CH Clegg, LA Correll, GS McKnight, Regulation of transcription by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA 86, 4887–4891 (1989). · DOI · Paper page
  45. F-X Yu, K-L Guan, The Hippo pathway: Regulators and regulations. Genes Development 27, 355–371 (2013). · DOI · Paper page
  46. P Chi, , ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467, 849–853 (2010). · DOI · Paper page
  47. RN Vellanki, L Zhang, A Volchuk, OASIS/CREB3L1 is induced by endoplasmic reticulum stress in human glioma cell lines and contributes to the unfolded protein response, extracellular matrix production and cell migration. PLoS One 8, e54060 (2013). · DOI
  48. B Denard, C Lee, J Ye, Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife 1, e00090 (2012). · DOI · Paper page
  49. HG Hers, The control of glycolysis and gluconeogenesis by protein phosphorylation. Philos Trans R Soc Lond B Biol Sci 302, 27–32 (1983). · DOI
  50. KC Patra, , Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24, 213–228 (2013). · DOI · Paper page
  51. J-S Moon, , Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem 286, 23808–23816 (2011). · DOI
  52. ML McCleland, , Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 19, 773–784 (2013). · DOI
  53. J Mitsushita, JD Lambeth, T Kamata, The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64, 3580–3585 (2004). · DOI · Paper page
  54. Y Adachi, , Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27, 4921–4932 (2008). · DOI
  55. JM Loo, , Extracellular metabolic energetics can promote cancer progression. Cell 160, 393–406 (2015). · DOI · Paper page
  56. JN Anastas, RT Moon, WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13, 11–26 (2013). · DOI · Paper page
  57. H Terasaki, T Saitoh, K Shiokawa, M Katoh, Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - beta-catenin - TCF signaling pathway. Int J Mol Med 9, 107–112 (2002).
  58. A Matsui, , DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer. Cancer Sci 100, 1923–1930 (2009). · DOI
  59. AI Vinik, , NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39, 713–734 (2010). · DOI · Paper page
  60. VE Gould, , Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 126, 243–257 (1987).
  61. RCS van Adrichem, , Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocr Connect 2, 172–177 (2013). · doi:10.1530/ec-13-0052
  62. B Jacobsson, A Carlström, VP Collins, L Grimelius, Transthyretin in endocrine pancreatic tumors. Am J Pathol 134, 465–471 (1989).
  63. E Jansen, TA Ayoubi, SM Meulemans, WJ Van de Ven, Neuroendocrine-specific expression of the human prohormone convertase 1 gene. Hormonal regulation of transcription through distinct cAMP response elements. J Biol Chem 270, 15391–15397 (1995). · DOI
  64. SRD Johnston, M Dowsett, Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer 3, 821–831 (2003). · DOI · Paper page
  65. DG Holland, , ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3, 167–180 (2011). · DOI
  66. DJ Slamon, , Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987). · DOI · Paper page
  67. S Cabodi, , p130Cas is an essential transducer element in ErbB2 transformation. FASEB 24, 3796–3808 (2010). · DOI
  68. JJ Northey, , Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol 28, 3162–3176 (2008). · DOI
  69. PV Monje, G Athauda, PM Wood, Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283, 34087–34100 (2008). · doi:10.1074/jbc.m802318200
  70. R Michalides, , Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5, 597–605 (2004). · DOI · Paper page
  71. R Crane, B Gadea, L Littlepage, H Wu, JV Ruderman, Aurora A, meiosis and mitosis. Biol Cell 96, 215–229 (2004). · DOI
  72. S Sen, , Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94, 1320–1329 (2002). · DOI · Paper page
  73. JR Bischoff, , A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17, 3052–3065 (1998). · DOI · Paper page
  74. Y-M Jeng, S-Y Peng, C-Y Lin, H-C Hsu, Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10, 2065–2071 (2004). · DOI · Paper page
  75. RD Carvajal, A Tse, GK Schwartz, Aurora kinases: New targets for cancer therapy. Clin Cancer Res 12, 6869–6875 (2006). · DOI · Paper page
  76. AO Walter, W Seghezzi, W Korver, J Sheung, E Lees, The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19, 4906–4916 (2000). · DOI · Paper page
  77. N Nakayama, , Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116, 2621–2634 (2010). · DOI · Paper page
  78. SA Ezhevsky, A Ho, M Becker-Hapak, PK Davis, SF Dowdy, Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 21, 4773–4784 (2001). · DOI · Paper page
  79. PO Humbert, , E2f3 is critical for normal cellular proliferation. Genes Dev 14, 690–703 (2000). · DOI · Paper page
  80. ER Andrechek, HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors. Oncogene 34, 217–225 (2015). · DOI
  81. CS Foster, , Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23, 5871–5879 (2004). · DOI
  82. M Oeggerli, , E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 25, 6538–6543 (2006). · DOI
  83. JJ McCloskey, EL Germain-Lee, JA Perman, LP Plotnick, AH Janoski, Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics 82, 379–382 (1988). · doi:10.1542/peds.82.3.379
  84. JA Carney, C Lyssikatos, MB Lodish, CA Stratakis, Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes. Hum Pathol 46, 40–49 (2015). · DOI
  85. H Zhong, RE Voll, S Ghosh, Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1, 661–671 (1998). · DOI · Paper page
  86. W Li, D Tan, MJ Zenali, RE Brown, Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 3, 238–243 (2010).
  87. Q Li, C Luo, CV Löhr, RH Dashwood, Activator protein-2α functions as a master regulator of multiple transcription factors in the mouse liver. Hepatol Res 41, 776–783 (2011). · doi:10.1111/j.1872-034x.2011.00827.x
  88. KR Holloway, , SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol 27, 480–490 (2013). · DOI
  89. JW Yang, , Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. Arch Pharm Res 31, 350–356 (2008). · DOI
  90. AC Bastidas, LC Pierce, RC Walker, DA Johnson, SS Taylor, Influence of N-myristylation and ligand binding on the flexibility of the catalytic subunit of protein kinase A. Biochemistry 52, 6368–6379 (2013). · DOI
  91. R Bernards, Finding effective cancer therapies through loss of function genetic screens. Curr Opin Genet Dev 24, 23–29 (2014). · DOI
  92. B Langmead, SL Salzberg, Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357–359 (2012). · DOI · Paper page
  93. A Dobin, , STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). · DOI · Paper page
  94. S Anders, PT Pyl, W Huber, HTSeq--A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015). · DOI · Paper page

Cited by

See all 109

Metadata

Authors
Simon, E. P., Freije, C. A., Farber, B. A., Lalazar, G., Darcy, D. G., Honeyman, J. N., Chiaroni-Clarke, R., Dill, B. D., Molina, H., Bhanot, U. K., La Quaglia, M. P., Rosenberg, B. R., & Simon, S. M.
Venue
Proceedings of the National Academy of Sciences
Published
2015-10-21
Volume
112
Issue
44
ISSN
  • 0027-8424
  • 1091-6490
Cited by
109
References
10
Language
en
Funders
  • HHS | NIH | National Center for Advancing Translational Sciences (CTSA 2UL1RR024143)
  • Leona M. and Harry B. Helmsley Charitable Trust (Instrumentation)
  • HHS | NIH | National Cancer Institute (5P30CA008748)
  • The Ira Sohn Research Conference Foundation (Support)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. https://app.cochat.ai/papers/10.1073/pnas.1424894112
The paper
Simon, E. P., Freije, C. A., Farber, B. A., Lalazar, G., Darcy, D. G., Honeyman, J. N., Chiaroni-Clarke, R., Dill, B. D., Molina, H., Bhanot, U. K., La Quaglia, M. P., Rosenberg, B. R., & Simon, S. M. (2015). Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1424894112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.